caa a22 4500 445336137 CHVBK 20180317142755.0 cr unu---uuuuu 170323e20110401xx s 000 0 eng 10.1245/s10434-010-1384-6 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1384-6 Perioperative Intra-Arterial and Systemic Chemotherapy for Pancreatic Cancer [Elektronische Daten] [Hiroshi Takamori, Keiichiro Kanemitsu, Masahiko Hirota, Osamu Ikeda, Hiroshi Tanaka, Toru Beppu, Yasuyuki Yamashita, Natsuo Oya, Hideo Baba] Background: Even after curative resection of pancreatic cancer, there is a high probability of systemic recurrence. This indicates that subclinical metastases are already present at the time of operation. The purpose of this study was to assess the feasibility and outcomes of patients who received a novel multimodality therapy combining pancreatic resection and intraoperative radiation therapy (IORT) with pre- and postoperative chemotherapy for pancreatic cancer. Methods: For eligible patients with pancreatic cancer, 5-FU was administered at a dose of 125 mg/m2/day on days 1-5 every week as a continuous pancreatic and hepatic arterial infusion, and gemcitabine was infused intravenously at a dose of 800 mg/m2 per day once per week for 2weeks for preoperative chemotherapy. Pancreatic resection combined with IORT was performed 1week after preoperative chemotherapy. Postoperative chemotherapy was performed in the same way as preoperative chemotherapy. We performed an intention-to-treat analysis for all enrolled patients. Results: This study enrolled 44 patients. The most common toxicities were hematological and gastrointestinal events. Grade 3/4 hematological toxicities were observed during preoperative chemotherapy, although there were no grade 3/4 nonhematological events. Postoperative chemotherapy-related toxicities were more critical and frequent than preoperative ones. There were no pre- or postoperative chemotherapy-associated deaths. Median overall survival was 36.5months with 30.5% overall 5-year survival. Conclusions: This multimodality therapy is feasible and promises to contribute to survival. It should be evaluated in a phase III setting. Society of Surgical Oncology, 2010 Takamori Hiroshi Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Kanemitsu Keiichiro Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Hirota Masahiko Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Ikeda Osamu Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Tanaka Hiroshi Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Beppu Toru Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Yamashita Yasuyuki Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Oya Natsuo Department of Radiation Oncology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Baba Hideo Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut Annals of Surgical Oncology Springer-Verlag 18/4(2011-04-01), 1110-1115 1068-9265 18:4<1110 2011 18 10434 https://doi.org/10.1245/s10434-010-1384-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1384-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Takamori Hiroshi Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Kanemitsu Keiichiro Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Hirota Masahiko Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Ikeda Osamu Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Tanaka Hiroshi Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Beppu Toru Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Yamashita Yasuyuki Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Oya Natsuo Department of Radiation Oncology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 700 1- Baba Hideo Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/4(2011-04-01), 1110-1115 1068-9265 18:4<1110 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer